Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents. (PubMed, Nutr Clin Pract) - Sep 30, 2026 - "GI adverse events with GLP-1-based therapies are predictable and manageable. A proactive, patient-centered approach is essential to optimize adherence, safety, and clinical outcomes as newer agents expand the therapeutic landscape."
Adverse events • Journal • Review • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Obesity • Pancreatitis • Type 2 Diabetes Mellitus
|
|
Ahmed Nadeem; Eisha Moazzam; Muhammad Ehsan; Samita Garg; Sara Valencia; Vikash Singhani; Winfield Scott Butsch
|